Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

NCT02297230 | Terminated Phase 1 Results DMC FDA Drug

• 1 other identifier: 10289
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

Paclitaxel 30 mg/m2 twice/week Trastuzumab 4mg/kg, loading dose, then 2 mg/kg weekly and Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total. \*\*Surgery: Patients will undergo lumpectomy and axillary node dissection or modified radical mastectomy within two months following discontinuation of pre-operative systemic therapy, contingent upon recovery of skin toxicity. Pathologic response will be evaluated at the time of surgery. Additional tissue samples will be collected from the surgical specimen for assessment of tumor molecular characteristics. \*\*\*All patients may undergo four cycles of post-operative Standard AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) or four cycles of post-operative epirubicin and Cyclophosphamide (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) if doxorubicin is not available Tamoxifen as well or any alternative antihormonal therapy may be prescribed for five years for patients with hormone receptor positive tumors. Herceptin (Trastuzumab) will be prescribed for a total of 1 year since first dose as per standard of care.

Conditions

Breast Cancer

Keywords

Locally Advanced Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Feasibility & Efficacy of Chemo-radiation While Targeting Treatment, Based on: Original Tumor Characteristics; to be Followed by [Need for] Conventional Post-operative Chemotherapy

  12/2014 (up to 12 years)

Secondary Outcomes (3)

• To Assess the Pathological Response Rate and Compare it to That Achieved in Our Previous Phase I-II Trials of Concurrent Chemo-radiation.

  12/2014 (up to 12 years)

• To Store Core Biopsies of the Original Tumor Before and After Treatment (From the Surgical Specimen) for Future Molecular Biology Studies in LABC.

  12/2014 (up to 12 years)

• To Acquire Descriptive Information on Patient Adherence to Therapy and on Quality of Life During Treatment.

  12/2014 (up to 12 years)

Study Arms (4)

Arm 1 Capecitabine and RT

EXPERIMENTAL

Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).

Radiation: Radiation Therapy (RT); Drug: Capecitabine

Arm 2 Paclitaxel/Trastuzumab and RT

EXPERIMENTAL

Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients. The first dose will be 4mg/kg given IV over 90 minutes. Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.

Radiation: Radiation Therapy (RT); Drug: Trastuzumab; Drug: Paclitaxel

Arm 3: Paclitaxel and RT

EXPERIMENTAL

Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.

Radiation: Radiation Therapy (RT); Drug: Paclitaxel

Arm 4: Paclitaxel/Trastuzumab and RT

EXPERIMENTAL

Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery \& thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.

Radiation: Radiation Therapy (RT); Drug: Trastuzumab; Drug: Paclitaxel

Interventions

Radiation Therapy (RT) RADIATION

Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.

Arm 1 Capecitabine and RT; Arm 2 Paclitaxel/Trastuzumab and RT; Arm 3: Paclitaxel and RT; Arm 4: Paclitaxel/Trastuzumab and RT

Capecitabine DRUG

Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).

Also known as: Xeloda

Arm 1 Capecitabine and RT

Trastuzumab DRUG

Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.

Also known as: Herceptin

Arm 2 Paclitaxel/Trastuzumab and RT; Arm 4: Paclitaxel/Trastuzumab and RT

Paclitaxel DRUG

Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).

Also known as: Taxol

Arm 2 Paclitaxel/Trastuzumab and RT; Arm 3: Paclitaxel and RT; Arm 4: Paclitaxel/Trastuzumab and RT

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Biopsy proven locally advanced breast cancer: STAGE IIB (T must be \> 3.0 cm, N0), IIIA (T0N2, T1N2, T2N2, T3N1), IIIB (T4N0-2).
• HER-2/neu positive ( DAKO 3+ by Immunohistochemistry or FISH positive if Dako 2+)
• Metastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodes.
• Measurable disease required according to the RECIST criteria (Response Evaluation Criteria in Solid Tumors)
• Adequate laboratory values:
• Hgb \> 10
• ANC(Absolute Neutrophil Count) \> 1500
• Platelets \> 150,000
• Cr \< 1.5
• Liver function \< 3 X normal.
• Patient \> 18 years of age.
• Medically and psychologically able to comply with all study requirements.
• ECOG (Eastern cooperative Oncology group) performance score 0-1.
• Signed informed consent.

You may not qualify if:

• Stage 0, Stage I, Stage IIA.
• Previous XRT(Radiation therapy) or chemotherapy.
• Presence of distant metastases documented clinically or radiographically with the exception of ipsilateral supraclavicular nodes.
• Inflammatory breast cancer.
• Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil.
• Exclude pregnant or lactating woman.
• Woman of childbearing potential with either a positive or no pregnancy test at baseline.
• Woman of childbearing potential not using a reliable and appropriate contraceptive method.
• (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential).
• Patient will agree to continue contraception for 30 days from the date of the last study drug administration.
• Serious concurrent infections.
• Clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias ) or myocardial infarction within the last 12 months.
• Patients who have had an organ allograft.
• Patients with severe renal impairment (creatinine clearance below 30 mL/min \[Cockcroft and Gault43\]). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min \[Cockcroft and Gault43\]) at baseline, a dose reduction to 75% of the XELODA starting dose is recommended. In patients with mild renal impairment (creatinine clearance 51-80 mL/min) no adjustment in starting dose is recommended.
• In phase I studies, those with any abnormal renal function, since toxicity will likely be affected by the presence of any significant renal dysfunction.

Sponsors & Collaborators

• NYU Langone Health: lead

Study Sites (1)

Weill Medical College of Cornell University

New York, New York, 10065, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Radiotherapy; Capecitabine; Trastuzumab; Paclitaxel

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Therapeutics; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Results Point of Contact

• Title: Sylvia Formenti
• Organization: New York University School of Medicine

lao2003@med.cornell.edu

646.962.4073

Study Officials

• Silvia C Formenti, M.D.

  Weill Medical College of Cornell University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 27, 2014
• First Posted: November 21, 2014
• Study Start: June 1, 2002
• Primary Completion: December 2, 2014
• Study Completion: December 2, 2014
• Last Updated: October 15, 2018
• Results First Posted: January 18, 2018

Record last verified: 2018-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)